Excessive daytime sleepiness (EDS) affects 10-20% of the population and is associated with substantial functional deficits. We identified 42 loci for self-reported EDS in GWAS of 452,071 individuals from the UK Biobank, with enrichment for genes expressed in brain tissues and in neuronal transmission pathways. We confirmed the aggregate effect of a genetic risk score of 42 SNPs on EDS in independent Scandinavian cohorts and on other sleep disorders (restless leg syndrome, insomnia) and sleep traits (duration, chronotype, accelerometer-derived sleep efficiency and daytime naps or inactivity). Strong genetic correlations were also seen with obesity, coronary heart disease, psychiatric diseases, cognitive traits and reproductive ageing.
EDS is a chief symptom of chronic insufficient sleep 1 as well as of several primary sleep disorders, such as sleep apnea, narcolepsy, and circadian rhythm disorders [2] [3] [4] [5] . Several disease processes and medications also associate with prevalent and incident EDS [6] [7] [8] [9] . EDS is estimated to contribute to risk for motor vehicle crashes, work-related accidents and loss of productivity, highlighting its public health importance 10, 11 . The clinical impact of EDS extends to a negative impact on cognition, behavior, and quality of life 12, 13 . Therefore, sleep interventions often identify reduction in EDS as a chief goal 14, 15 . EDS is also associated with an increased risk for cardio-metabolic disorders, psychiatric problems and mortality 9, 16, 17 through pathways that may be causal, bi-directional, or reflect pleiotropic effects.
While EDS occurs in a variety of settings associated with insufficient sleep, there is large interindividual variability in levels of EDS that is not fully explained by sleep duration, sleep quality or chronic disease. Experimental studies have shown that there is also individual vulnerability to EDS following sleep restriction 18, 19 . The heritability of EDS is estimated to be between 0.37 to 0.48 in twin studies, 0.17 in family studies, and between 0.084 to 0.17 in GWAS 20, 21 , suggesting that genetic factors contribute to variation in sleepiness. Despite multiple candidate gene studies [22] [23] [24] 25, 26 , including one from the first genetic release of the UK Biobank 21 , few significant genetic variants have been reported, likely reflecting the heterogeneous and multifactorial etiology of the phenotype and low statistical power. Here, we extend our EDS GWAS to the full UK Biobank dataset 27 , enabling identification of multiple genetic variants and molecular pathways that may contribute to EDS.
In the UK Biobank, 27 452,071 participants of European genetic ancestry self-reported frequency of EDS using the question: "How likely are you to doze off or fall asleep during the daytime when you don't mean to? (e.g.: when working, reading or driving)", with the answer categories analysis of these, likely due to the lower power, inconsistent questionnaires across different cohorts and the multi-factorial etiology of EDS (Supplementary Table 10 ). However, a genetic risk score (GRS) of all 42 EDS loci weighted by the effect estimates from our primary EDS GWAS was associated with increased EDS in a meta-analysis of HUNT, FINRISK and Health 2000 (Fisher's p=0.001; Supplementary Table 10) .
Heterogeneous effects of EDS loci on other sleep traits
The 42 EDS-associated genetic variants likely influence EDS through different mechanisms.
Therefore, to dissect heterogeneity, we tested for association of the combined GRS and individual SNPs with subjective and objective measures of sleep patterns and disorders (Table 1 and Supplementary Table 11) .
A GRS of all 42 variants was associated with self-reported shorter sleep duration, morning chronotype, increased insomnia risk, increased frequency of daytime napping, and with accelerometry-assessed lower sleep efficiency and increased duration of daytime inactivity (Table 1 ). The EDS GRS was not associated with 7-day accelerometry-derived continuous sleep duration, which may reflect differences in self-reported habitual sleep vs. accelerometryestimated sleep, different time points in data collection (accelerometry data were collected 5-7 years after questionnaires), lower power given smaller sample size in accelerometry data, or recall or other biases in the self-report such as from reporting in 1 hour increments.
Individual EDS increasing alleles at PATJ and PLCL1 were also associated with morning chronotype (as previously reported 31, 49 ) with both morning chronotype and short sleep duration, suggesting common genetic factors. Consistently, adjusting for sleep disturbance traits (ICD10 code defined sleep apnea or narcolepsy, or self-reported sleep duration hours, frequent insomnia symptoms or chronotype) together attenuated effect estimates for several loci, suggesting that these genetic variants influence EDS through altered sleep patterns; however, adjustment for any trait alone only minimally altered effect estimates at select individual loci (Supplementary Table 5 ).
Using 7-day accelerometry-derived data available in a subset of the UK Biobank (N=85,388), we observed associations of several EDS alleles with reduced sleep efficiency (e.g., SNX17) whereas others were associated with increased sleep efficiency (e.g., PLCL1), suggesting that genetic mechanisms may lead to EDS through effects on increased sleep fragmentation (i.e., low sleep efficiency) or increased sleep propensity (i.e., high sleep efficiency), respectively. Therefore, we performed clustering analysis on EDS risk alleles at 42 loci according to their association effect sizes (z-scores) with objective estimates of sleep efficiency, sleep duration, and number of sleep bouts, and self-reported frequent insomnia symptoms. We interpreted EDS alleles showing patterns of association with higher sleep efficiency, longer sleep duration, fewer discrete sleep bouts and fewer insomnia symptoms as reflective of greater sleep propensity; whereas EDS alleles associated with these sleep traits in a largely inverse manner were interpreted as reflective of disturbed sleep or a sleep fragmentation phenotype (Fig. 2) . GRS of EDS loci stratified by the two clusters support our interpretation, with sleep propensity loci showing robust associations with early circadian traits, (e.g. morning chronotype P=1.22×10 -10 ; 
Functional effects of loci
The 42 loci lie in genomic regions encompassing 164 genes (Supplementary Table 12) , and 3 associations are in strong linkage disequilibrium with known GWAS associations for other traits, including blood cell count, HDL cholesterol and caffeine metabolism [52] [53] [54] [55] . Genes at multiple loci have been implicated in Mendelian syndromes or in experimental studies in mouse or fly models.
Eighteen loci harbor one or more genes with potential drug targets 56,57 .
We performed fine mapping analyses for potential causal variants using PICS 58 and identified 33 variants within 25 EDS loci with a causal probability larger than 0.2 (Supplementary Table   13 ). The majority of likely causal variants were intronic (65%) followed by non-coding transcript variants (8%) and nonsense mediated decay (NMD) transcript variants (7%) (Supplementary Fig. 5 , we further observed the pleiotropic locus at rs13135092 (SLC39A8 60 ) to be significantly associated with bilateral putamen and striatum volume in the UK Biobank (p<2.8×10 -7 ; N=9,707; Supplementary Fig. 6 ). This could be of particular interest given the importance of these central brain centers in influencing motor and emotional behaviors, and emerging data implicating these centers in the integration of behavioral inputs that modulate arousal and sleep-wake states 61, 62 .
1

Gene-based, pathway and tissue enrichment analyses
Gene-based analyses using PASCAL 63 identified 94 genes associated with EDS (p<2.29×10 -6 ) ( Supplementary Table 14) , of which 63 overlapped with genes under significant association peaks shown in Supplementary Table 16 and 17) .
Genes at loci showing clustering with sleep propensity phenotypes (n=67) showed enriched expression in brain tissues including cortex, hippocampus, cerebellum, and amygdala (P<10 -3 ; Supplementary Fig. 7B ). In contrast, no tissues were enriched in expression of genes that showed clustering with sleep fragmentation phenotypes (n=97) ( Supplementary Fig. 7C ), suggesting that the mechanisms associated with sleep fragmentation may be more complex, reflective of multifactorial influences. Pathway and ontology analyses results for clustered genes using FUMA also reveal different patterns (Supplementary Fig. 8 and 9 ).
The heritability of EDS explained by genome-wide SNPs was estimated at 6.9% (SE=1%). To investigate the genetic correlation between EDS and other common disorders, we tested the proportion of genetic variation of EDS shared with 233 other traits with published GWAS summary statistics in LDSC 72 . After adjusting for multiple comparisons, significant positive genetic correlations were observed for EDS with obesity traits, coronary heart disease, and psychiatric traits (P<0.0001) (Supplementary Table 19 ). The genetic correlations of EDS with coronary artery disease and psychiatric traits persisted after adjusting for BMI (Figure 2 ), perhaps partially reflecting shared neurologic or neuroendocrine factors, such as those that underlay insomnia and short sleep with cardiac and psychiatric traits 73, 74 . Consistently suggestive negative genetic correlations for EDS with subjective well-being and reproductive traits (age at menarche and age at first birth) were also observed (P<0.005). P-values significant after correction for 14 traits are shown in bold.
* Sleep traits used to cluster sleep propensity and sleep fragmentation phenotypic subtypes. P-values significant after correction for 9 traits are shown in bold. Figure 3 . Top significant genetic correlations (r g ) between EDS and published summary statistics of independent traits using genomewide summary statistics using LD score regression (LDSC). Blue color indicates positive genetic correlation and red color indicates negative genetic correlation. Larger colored squares correspond to more significant P values, and asterisks indicate significant (P <2.2×10 -4 ) genetic correlations after adjusting for multiple comparisons of 224 available traits. All genetic correlations in this report can be found in tabular form in Supplementary Table 20 . Figure 4 . Radial plot of two-sample Mendelian randomization between (A) BMI and (B) Type 2 diabetes with EDS outcome using IVW and MR-Egger tests. The x-axis is the inverse standard error (square root weights in the IVW analysis) for each SNP. The y-axis scale represents the ratio estimate for the causal effect of an exposure on outcome for each SNP ( ) multiplied by the same square root weight.
Methods
Population and study design
The discovery analysis was conducted on participants of European ancestry from the UK Biobank study 27 . The UK Biobank is a prospective study that has enrolled over 500,000 people aged 40-69 living in the United Kingdom. Baseline measures collected between 2006 -2010, including self-reported heath questionnaire and anthropometric assessments, were used in this analysis. Participants taking any self-reported sleep medication (described elsewhere 73 ) were excluded. 452,071 individuals of European ancestry were studied with available phenotypes and genotyping passing quality control, as described below.
Excessive daytime sleepiness and covariate measurements
Self-reported excessive daytime sleepiness (EDS) was ascertained in the UK Biobank using the question "How likely are you to dose off or fall asleep during the daytime when you don't mean to? (e.g. when working, reading or driving)" with the response options of "Never/rarely", "sometimes", "often", "all of the time", "do not know", and "prefer not to answer". Participants reporting "do not know" and "prefer not to answer" were set to missing. Other responses were coded continuously as 1 to 4 corresponding to the severity of EDS. The primary covariates used were self-reported age and sex, and body mass index (BMI) calculated as weight/height 2 .
Covariates used in the sensitivity analyses include potential confounders (depression, social economic status, alcohol intake frequency, smoking status, caffeine intake, employment status, marital status, and use of psychiatric medications) and indices of sleep disorders and sleep traits (daytime napping, sleep apnea, narcolepsy, sleep duration, insomnia, and chronotype).
Depression was recorded as a binary variable (yes/no) corresponding to question "Ever depressed for a whole week?". Social economic status was measured by the Townsend Deprivation Index based on aggregated data from national census output areas in the UK.
Alcohol intake frequency was coded as a continuous variable corresponding to "daily or almost daily", "three or four times a week", "once or twice a week", "once to three times a month", "special occasions only", and "never" drinking alcohol. Smoking status was categorized as "current', "past", or "never" smoked. Caffeine intake was coded continuously corresponding to self-reported cups of tea/coffee per day. Employment status was categorized as "employed", "retired", "looking after home and/or family", "unable to work because of sickness or disability", "unemployed", "doing unpaid or voluntary work", or "full or part-time student". Day napping was coded continuously ("never/rarely", "sometimes" or "usually") responding to the question "Do you have a nap during the day?" Sleep apnea cases (N=5,571) were identified as a union of self-reported and International Classification of Diseases (ICD)-10 coded (G47.3) sleep apnea.
Narcolepsy cases (N=7) were determined by the ICD-10 code (G47.4) Insomnia was recorded as "never/rare", "sometimes" or "usually" responding to the question "Do you have trouble falling asleep at night or do you wake up in the middle of the night?". Individuals reported "usually"
were considered as frequent insomnia symptom cases. Sleep duration was recorded as discrete integers in response to the question "About how many hours sleep do you get in every 24 hours (please include naps)". In this study, short sleep was defined by sleep duration shorter than 7 hours and long sleep was defined by sleep duration longer than 8 hours. Chronotype was categorized as "definitely a 'evening' person", "more an 'evening' than a 'morning' person", "more a 'morning' than 'evening' person", and "definitely an 'morning' person". Secondary analyses were performed on participants further excluding shift workers, psychiatric mediation users, and participants with chronic and psychiatric illness (defined elsewhere 73 , N=255,426).
Activity-monitor derived measures of sleep
Raw accelerometer data (.cwa) were collected using open source Axivity AX3 wrist-worn triaxial accelerometers (https://github.com/digitalinteraction/openmovement) in 103,711
individuals from the UK Biobank for up to 7 days 80 . We converted .cwa files to .wav files using Omconvert (https://github.com/digitalinteraction/openmovement/tree/master/Software/AX3/omconvert) 80,81 .
Time windows of sleep (SPT-window) and activity levels were extracted for each 24-hour period using the R package GGIR (https://cran.r-project.org/web/packages/GGIR/GGIR.pdf) [82] [83] [84] .
Briefly, for each individual, a 5-minute rolling median of the absolute change in z-angle (representing the dorsal-ventral direction when the wrist is in the anatomical position) across a 24-hour period. The 10th percentile of the output was used to construct an individual's threshold, distinguishing periods with movement from non-movement. Inactivity bouts were defined as inactivity of at least 30 minutes duration. Inactivity bouts with less than 60 minutes gaps were combined to blocks. The SPT-window was defined as the longest inactivity block, with sleep onset as the start of the block and waking time as the end of the block 85 . We applied exclusion criteria based on accelerometer data quality including 1) none-zero or missing in "data problem indicator" (Field 90002); 2) 0 in "good wear time" (Field 90015); 3) 0 in "good calibration"
(Field 90016); 4) 0 in "calibrated on own data" (Field 90017); 5) "data recording errors" (Field 90182) > 788 (Q 3 +1.5×IQR); and 6) none-zero in "interrupted recording periods" (Filed 90180).
Accelerometry data from 85,502 participants of European ancestry passed quality control and were analyzed in this study.
The distributions of accelerometer data are described in Supplementary Table 1 . The details of each measurement are as follows. L5 and M10 were the least-active five-hour window and mostactive ten-hour window for each day estimated from a moving average of a contiguous five/tenhour window. The L5 timing was defined as the number of hours elapsed from the previous midnight whereas M10 was defined as the number of hours elapsed from the previous midday.
Sleep midpoint was the midpoint between the start and end of the SPT-window. L5, M10, and sleep midpoint variables capture the circadian characteristics of an individual. Sleep episodes within the SPT-window were defined as periods of the z-axis angle change less than 5° for at least 5 minutes 83 . Sleep duration in a SPT-window was calculated as the sum of all sleep episodes. The mean and standard deviation of sleep duration across all SPT-windows were investigated in this study. Sleep efficiency was calculated as sleep duration divided the total SPT-window duration in a SPT-window. Sleep fragmentation was examined by counting the number of sleep episodes of at least 5 minutes separated by at least 5 seconds of wakefulness within a SPT-window. Diurnal inactivity duration was the total duration of estimated bouts of inactivity that fell outside of the SPT-window in 24 hours, which included both inactivity and naps. SNPs with minor allele frequency <0.001, genotype calling triplet probability < 0.1, or imputation quality <0.8 were further excluded from the current analyses. The detailed description of genotyping, QC, and imputation are available elsewhere 86 . We further performed K-means clustering using the principal components (PCs) of ~100,000 high quality genotyped SNPs (missingness <1.5% and MAF >2.5%) and identified 453,964 participants of European ancestry.
Genotyping and quality control
Genome-wide association analysis
We performed a genome-wide association analysis (GWAS) of self-reported EDS using 452,071
individuals of European ancestry in the UK Biobank across autosomes. A linear mixed regression model was applied adjusting for age, sex, genotyping array, 10 PCs and genetic relatedness matrix, using EDS as a continuous variable of 4 integers, using BOLT-LMM 28 .
Similar linear mixed regression analyses were performed additionally adjusting for BMI and stratified by sex. Secondary GWAS excluding related individuals, shift workers, individuals who used psychiatric medications, and participants with chronic health and psychiatric illness (N=255,426) was performed adjusting for age, sex, genotyping array and 10 PCs in PLINK 1.9 87 .
Trait heritability was estimated using BOLT-REML 28 . Genome-wide significance level was set at 5×10 -8 . Gene-sex and gene-health status interaction analyses were performed on unrelated individuals using a linear regression model in PLINK. Conditional analyses to dissect independent signals in significant genomic regions were performed using GCTA-COJO 88 .
Variant annotation was performed using PICS 58 .
Post-GWAS analyses
Sensitivity and stratification analyses of significant loci 
Gene, pathway and tissue-enrichment analyses
We further examined the genes within genome-wide significant loci using gene-based, pathway, and tissue enrichment analyses 63, 67, 68, 90 . Gene-based analysis was performed using PASCAL 63 .
Pathway and ontology enrichment analyses were performed using FUMA 90 and EnrichR 67,68 .
Tissue enrichment analysis was performed using MAGMA 65 in FUMA, which controlled for gene size. Pathway and tissue enrichment analyses were also performed on genes within loci belonging to sleep propensity and sleep fragmentation clusters separately.
We constructed a weighted GRS comprised of the 42 significant EDS loci and tested for associations with other self-reported sleep traits (sleep duration, long sleep duration, short sleep duration, insomnia, chronotype, and day naps), and 7-day accelerometry traits in the UK Biobank 73, 74, 79, 89 . Weighted GRS analyses were performed by summing the products or risk allele count multiplied by the effect estimate reported in the primary GWAS of EDS using R package gds (https://cran.r-project.org/web/packages/gds/gds.pdf). We also tested the GRSs of reported loci for insomnia, sleep duration, short sleep, long sleep, day naps, chronotype, restless leg syndrome (RLS), narcolepsy, and coffee consumption associated with EDS using the same T 
Supplementary Materials:
Supplementary Tables 1-22 Supplementary Figures 1-9 
